Upcoming Webinars

Join us on March 24th at 2:00 PM Eastern Time as Jeremy Smith, Director of Business Analytics at Audentes Therapeutics and Dan Fisher, Principal Consultant at IPM.ai discuss how non-traditional real-world data combined with the power of machine learning and artificial intelligence deepened disease understanding and shortened the diagnostic journey of X-Linked Myotubular Myopathy (XLMTM).

Audentes Therapeutics is developing AT132 for the treatment of XLMTM, a rare, life-threatening neuromuscular disease characterized by extreme muscle weakness, respiratory failure and high mortality. The condition, affecting about 1 in 40-50,000 newborn males, is caused by a gene mutation that leads to a lack or dysfunction of myotubularin, a protein that is needed for normal development, maturation and function of skeletal muscle cells. 

You'll learn firsthand how we leveraged a top KOL’s home-grown patient registry in a privacy-safe fashion and unified it with a robust real-world data universe to uncover the XLMTM patient journey, discover symptomatology that was not previously understood and identify undiagnosed and misdiagnosed patients to ultimately shorten the diagnostic timeline.